Serial Blood-based Analysis of AR-V7 in Men with Advanced Prostate Cancer

Overview

Journal Ann Oncol

Publisher Elsevier

Specialty Oncology

Date 2015 Jun 29

PMID 26117829

Citations 88

Authors

M Nakazawa

C Lu

Y Chen

C J Paller

M A Carducci

M A Eisenberger

J Luo

E S Antonarakis

Affiliations

Soon will be listed here.

Abstract

Background: We previously showed that pretreatment detection of androgen receptor splice variant-7 (AR-V7) in circulating tumor cells (CTCs) from men with castration-resistant prostate cancer is associated with resistance to abiraterone and enzalutamide, but not to taxane chemotherapies. Here, we conducted serial measurements of AR-V7 and evaluated patterns of longitudinal AR-V7 dynamics over the course of multiple sequential therapies.

Patients And Methods: Metastatic prostate cancer patients treated at Johns Hopkins with AR-directed therapies or taxane chemotherapies underwent serial liquid biopsies for CTC-based AR-V7 analysis at baseline, during therapy, and at progression. We used a CTC enrichment platform followed by multiplexed reverse-transcription polymerase chain reaction analysis to detect full-length androgen receptor and AR-V7 transcripts. Patients selected for inclusion in this report were those who provided ≥4 CTC samples, at least one of which was AR-V7 positive, over the course of ≥2 consecutive therapies.

Results: We identified 14 patients who received a total of 37 therapies and contributed 70 CTC samples for AR-V7 analysis during a median follow-up period of 11 months. Three patients remained AR-V7 positive during the entire course of therapy. The remainder underwent transitions in AR-V7 status: there were eight instances of 'conversions' from AR-V7-negative to -positive status (during treatment with first-line androgen deprivation therapy, abiraterone, enzalutamide, and docetaxel), and six instances of 'reversions' from AR-V7-positive to -negative status (during treatment with docetaxel and cabazitaxel).

Conclusions: AR-V7 is a dynamic marker, and transitions in AR-V7 status may reflect selective pressures on the tumor exerted by therapeutic interventions. While 'conversions' to AR-V7-positive status were observed with both AR-directed therapies and taxane chemotherapies, 'reversions' to AR-V7-negative status only occurred during taxane therapies. Serial blood-based AR-V7 testing is feasible in routine clinical practice, and may provide insights into temporal changes in tumor evolution.

Citing Articles

A novel peptide encoded by circSRCAP confers resistance to enzalutamide by inhibiting the ubiquitin-dependent degradation of AR-V7 in castration-resistant prostate cancer.

Meng X, Wu Q, Cao C, Yang W, Chu S, Guo H J Transl Med. 2025; 23(1):108.

PMID: 39844192 PMC: 11755828. DOI: 10.1186/s12967-025-06115-z.

LX1 Dual Targets AR Variants and AKR1C3 in Advanced Prostate Cancer Therapy.

Ning S, Armstrong C, Xing E, Leslie A, Gao R, Sharifi M Cancer Res. 2024; 84(21):3617-3628.

PMID: 39088701 PMC: 11534543. DOI: 10.1158/0008-5472.CAN-24-0440.

NanoLuc Binary Technology as a methodological approach: an important new tool for studying the localization of androgen receptor and androgen receptor splice variant V7 homo and heterodimers.

Guzman J, Weigelt K, Neumann A, Tripal P, Schmid B, Winter Z BMC Cancer. 2024; 24(1):346.

PMID: 38500100 PMC: 10949640. DOI: 10.1186/s12885-024-12110-2.

The Detection and Negative Reversion of Circulating Tumor Cells as Prognostic Biomarkers for Metastatic Castration-Resistant Prostate Cancer with Bone Metastases Treated by Enzalutamide.

Nakamura S, Nagata M, Nagaya N, Ashizawa T, Hirano H, Lu Y Cancers (Basel). 2024; 16(4).

PMID: 38398163 PMC: 10886552. DOI: 10.3390/cancers16040772.

Clinical characteristics of patients with metastatic castration-resistant prostate cancer after treatment with combined androgen blockade.

Obinata D, Hashimoto S, Uchida H, Nakahara K, Yoshizawa T, Mochida J BMC Urol. 2023; 23(1):74.

PMID: 37118708 PMC: 10148407. DOI: 10.1186/s12894-023-01233-6.

References

Mostaghel E, Marck B, Plymate S, Vessella R, Balk S, Matsumoto A . Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res. 2011; 17(18):5913-25. PMC: 3184252. DOI: 10.1158/1078-0432.CCR-11-0728. View

Taplin M, Bubley G, Shuster T, FRANTZ M, Spooner A, Ogata G . Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med. 1995; 332(21):1393-8. DOI: 10.1056/NEJM199505253322101. View

Hu R, Isaacs W, Luo J . A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities. Prostate. 2011; 71(15):1656-67. PMC: 3360954. DOI: 10.1002/pros.21382. View

Bianchini D, Lorente D, Rodriguez-Vida A, Omlin A, Pezaro C, Ferraldeschi R . Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone. Eur J Cancer. 2013; 50(1):78-84. DOI: 10.1016/j.ejca.2013.08.020. View

Hu R, Dunn T, Wei S, Isharwal S, Veltri R, Humphreys E . Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 2009; 69(1):16-22. PMC: 2614301. DOI: 10.1158/0008-5472.CAN-08-2764. View

Chang K, Li R, Papari-Zareei M, Watumull L, Zhao Y, Auchus R . Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proc Natl Acad Sci U S A. 2011; 108(33):13728-33. PMC: 3158152. DOI: 10.1073/pnas.1107898108. View

Yeh S, Miyamoto H, Shima H, Chang C . From estrogen to androgen receptor: a new pathway for sex hormones in prostate. Proc Natl Acad Sci U S A. 1998; 95(10):5527-32. PMC: 20411. DOI: 10.1073/pnas.95.10.5527. View

Lorente D, Mateo J, Perez-Lopez R, de Bono J, Attard G . Sequencing of agents in castration-resistant prostate cancer. Lancet Oncol. 2015; 16(6):e279-92. DOI: 10.1016/S1470-2045(15)70033-1. View

Koivisto P, Kononen J, Palmberg C, Tammela T, Hyytinen E, Isola J . Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res. 1997; 57(2):314-9. View

10.

Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C . In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet. 1995; 9(4):401-6. DOI: 10.1038/ng0495-401. View

11.

Guo Z, Yang X, Sun F, Jiang R, Linn D, Chen H . A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res. 2009; 69(6):2305-13. PMC: 2672822. DOI: 10.1158/0008-5472.CAN-08-3795. View

12.

Joseph J, Lu N, Qian J, Sensintaffar J, Shao G, Brigham D . A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. Cancer Discov. 2013; 3(9):1020-9. DOI: 10.1158/2159-8290.CD-13-0226. View

13.

Dehm S, Tindall D . Alternatively spliced androgen receptor variants. Endocr Relat Cancer. 2011; 18(5):R183-96. PMC: 3235645. DOI: 10.1530/ERC-11-0141. View

14.

Titus M, Schell M, Lih F, Tomer K, Mohler J . Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res. 2005; 11(13):4653-7. DOI: 10.1158/1078-0432.CCR-05-0525. View

15.

Nakazawa M, Antonarakis E, Luo J . Androgen receptor splice variants in the era of enzalutamide and abiraterone. Horm Cancer. 2014; 5(5):265-73. PMC: 4167475. DOI: 10.1007/s12672-014-0190-1. View

16.

Locke J, Guns E, Lubik A, Adomat H, Hendy S, Wood C . Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res. 2008; 68(15):6407-15. DOI: 10.1158/0008-5472.CAN-07-5997. View

17.

Chen C, Welsbie D, Tran C, Baek S, Chen R, Vessella R . Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004; 10(1):33-9. DOI: 10.1038/nm972. View

18.

van Soest R, de Morree E, Kweldam C, de Ridder C, Wiemer E, Mathijssen R . Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer. Eur Urol. 2014; 67(6):981-985. DOI: 10.1016/j.eururo.2014.11.033. View

19.

Zhu H, Garcia J . Targeting the adrenal gland in castration-resistant prostate cancer: a case for orteronel, a selective CYP-17 17,20-lyase inhibitor. Curr Oncol Rep. 2013; 15(2):105-12. DOI: 10.1007/s11912-013-0300-1. View

20.

Loriot Y, Bianchini D, Ileana E, Sandhu S, Patrikidou A, Pezaro C . Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann Oncol. 2013; 24(7):1807-1812. DOI: 10.1093/annonc/mdt136. View